Chloroplast-derived anthrax and other vaccine antigens: their immunogenic and immunoprotective properties
Abbreviated Journal Title
Expert Rev. Vaccines
anthrax vaccine; chloroplast genetic engineering; genetically modified; crops; immunization; mucosal immunity; oral delivery; protective; antigens; systemic immunity; vaccines; HEAT-LABILE ENTEROTOXIN; HIGH-YIELD EXPRESSION; VP7 FUSION PROTEIN; LACTUCA-SATIVA L.; B-SUBUNIT; TRANSGENIC POTATO; TOBACCO CHLOROPLASTS; PROTECTIVE ANTIGEN; CANINE PARVOVIRUS; NEUTRALIZING ANTIBODIES; Immunology
Transgenic plants offer many advantages, including low cost of production (by elimination of fermenters), storage and transportation, heat stability, absence of human pathogens, protection of antigens in the stomach through bioencapsulation (when delivered orally), elimination of the need for expensive purification and sterile injections and generation of both systemic and mucosal immunity. Recent studies have demonstrated that chloroplast-derived anthrax-protective antigen elicits effective immune responses, develops neutralizing antibodies, confers complete protection against anthrax lethal toxin challenge and produces 360 million doses of vaccine in one acre of transgenic plants. Chloroplast-derived vaccine antigens are efficacious against bacterial, fungal, viral and protozoan pathogens.
Expert Review of Vaccines
"Chloroplast-derived anthrax and other vaccine antigens: their immunogenic and immunoprotective properties" (2006). Faculty Bibliography 2000s. 4692.